A novel PDHK inhibitor restored cognitive dysfunction and limited neurodegeneration without affecting amyloid pathology in 5xFAD mouse, a model of Alzheimer’s disease
These results suggest ameliorating metabolic deficits by activating PDH by Compound A can limit neurodegeneration and is a promising therapeutic strategy for treating AD.
Authors
- Kana Harada
- Chihiro Okuma
- Takashi Kawai (ORCID: https://orcid.org/0000-0002-3557-7649)
- Katsuya Sakimura
- Takashi Suzuki (ORCID: https://orcid.org/0000-0002-3575-393X)
- Yuji Ishida
- Reiko Nashida
- Gregory M. Cole
Institutions
- Japan Tobacco (United States) (US)
- Geriatric Research Education and Clinical Center (US)
- VA Greater Los Angeles Healthcare System (US)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1186/s13195-024-01552-2
- Citations
- 11
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.59
Funders
- University of California, Los Angeles